title: Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.
abstract: OBJECTIVE
  Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM).
  
  
  METHODS
  Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted ≥3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly.
  
  
  RESULTS
  Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements ≥15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered.
  
  
  CONCLUSIONS
  Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Hospital São João, University of Porto, Porto, Portugal.
authors.forename: Angela M
authors.initials: AM
authors.lastname: Carneiro
authors.forename: Rufino M
authors.initials: RM
authors.lastname: Silva
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Veludo
authors.forename: Augusto
authors.initials: A
authors.lastname: Barbosa
authors.forename: José M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Manuel S
authors.initials: MS
authors.lastname: Falcão
authors.forename: Elisete M
authors.initials: EM
authors.lastname: Brandão
authors.forename: Fernando M
authors.initials: FM
authors.lastname: Falcão-Reis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002825:Chorioretinitis / Q000150:complications; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications*; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab